Related Experiment Videos
[Atherosclerosis and simvastatin: new questions for the new millennium]
1Dipartimento delle Malattie del Cuore, Azienda Ospedaliera San Filippo Neri di Roma.
Insights
Simvastatin significantly reduces mortality and myocardial infarction in coronary artery disease patients. This lipid-lowering therapy offers broad benefits beyond cholesterol reduction for cardiovascular event prevention.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Coronary artery disease (CAD) remains a leading cause of morbidity and mortality in Western nations.
- Lipid levels are strongly correlated with the risk of coronary events.
- Statins, particularly simvastatin, have proven effective in reducing cardiovascular mortality and events.
Purpose:
- To review the established benefits of simvastatin in managing coronary artery disease.
- To explore the pleiotropic effects of simvastatin beyond lipid reduction.
- To discuss future research directions and clinical applications of simvastatin therapy.
Summary:
- Simvastatin therapy demonstrably reduces total and cardiac mortality, myocardial infarction, and coronary events.
- Beyond cholesterol reduction, simvastatin improves endothelial function, reduces inflammation, and mitigates oxidative stress.
- Ongoing trials are investigating high-dose simvastatin, combination therapies, and its role in high-risk patients and acute coronary syndromes.
Impact:
- Simvastatin provides a rational basis for its widespread clinical use in primary and secondary prevention of CAD.
- Evidence from major trials supports broader, earlier, and more intensive use of simvastatin.
- Simvastatin is effective in both preventing and treating acute coronary syndromes, improving patient outcomes.
Abstract:
Coronary artery disease is still associated with high morbidity and mortality in Western countries. Lipid blood levels have a tight correlation with the risk of coronary events, and the results of many trials on lipid-lowering therapy (and particularly on simvastatin) demonstrated a significant reduction in total and cardiac mortality, and in the incidence of myocardial infarction and coronary events; even the progression of coronary stenosis has been reduced by treatment with statins. Beyond cholesterol reduction, simvastatin exerts many favorable effects on endothelial function, inflammatory activity, expression of pro-thrombotic factors and oxidative stress, yielding a rational basis for its important clinical positive effects, both in primary and secondary prevention of coronary disease. Future developments, which are the subjects of many planned or ongoing clinical trials, are related to the treatment of high-risk patients, the evaluation of the efficacy of elevated simvastatin dosages and of a deep reduction in cholesterol blood levels, the interaction between simvastatin and other drugs (antioxidant compounds, vitamins, antiplatelet drugs) or interventional procedures (percutaneous transluminal coronary angioplasty). Particularly, the Heart Protection Study, the A to Z trial, and the SEARCH and SMART studies will provide important data on a wider, earlier and greater use of simvastatin, which has been demonstrated effective both in the prevention and treatment of acute coronary syndromes.